Livalo package insert
Livalo package insert
LIVALO® (pitavastatin) Tablet 1 mg, 2 mg, and 4 mg Kowa Pharmaceuticals America, Inc. Package Insert livalo package insert – Product Labeling. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded [see Drug. Clinically indicated thereaf-----To repor -----N. LIVALO® (pitavastatin) Tablet. 1) Recommended dosage is 300 mg taken orally twice daily with or without food. , Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human, Xenobio Metabol Dispos, 1999;14:415–24 Epidemiology and Management of Hyperlipidemia. 10 OVERDOSAGE No specific treatment for LIVALO overdose is known. Package Insert – Product Labeling LIVALO®(pitavastatin) Tablet 1 mg, 2 mg, and 4 mg Kowa Pharmaceuticals America, Inc. See the lipid results in Table 10 Page 2: Kowa Pharmaceuticals America, Inc. 6 The newest entry in this class on the U. LIVALO significantly reduced plasma LDL-C, non-HDL-C, TC, and Apo-B compared to placebo. Montgomery, AL 36117 Package Insert – Product Labeling Version of May 2013 Version 7. See the lipid results in Table 10 LIVALO® (pitavastatin) Tablet. The chemical name for pitavastatin is (+)monocalcium bis { (3R, 5S, 6E)-7- [2-cyclopropyl-4- (4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}. Market is pitavastatin (Livalo, Kowa). Specifically, pharmacists have access to drug information from a variety of resources, including print publications, subscription-based electronic databases (e. 0 - November 2016 - LIV-RA-0097 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIVALO®safely and effectively When titrating to 4 mg, LIVALO provides a 45% mean LDL-C reduction. The reductions in LDL-C, Apo-B, TC, and non-HDL-C were dose dependent. RZD3KDUDPFHXWLFDOV$PHULFD ,QF 9 0D\ /,9 5$. Montgomery, AL 36117 Package Insert – Product Labeling Version of November 2016 Version 9. Elfinavir : Do not exceed 40 mg atorvastatin daily Lopinavir plus ritonavir, simeprevir, fibric acid derivatives, erythromycin, azole antifungals, lipid-modifying doses. Contact Poison Control (1-800-222-1222) for latest recommendations Table 5. In patients taking erythromycin, a dose of LIVALO 1 mg once daily should not be exceeded [see Drug Interactions (7. The recommended starting LIVALO dosage is 2 mg once daily (2. Individualize the dose of LIVALO according to patient characteristics, goal of therapy, and response. Pitavastatin is odorless and occurs as white to pale-yellow powder LIVALO significantly reduced plasma LDL-C, non-HDL-C, TC, and Apo-B compared to placebo. Montgomery, AL: Kowa Pharmaceuticals America, Inc. After initiation or upon titration of LIVALO, analyze lipid levels after 4 weeks and adjust the dosage accordingly LIVALO 1 mg once daily and a maximum dose of LIVALO 2 mg once daily. 73 m 2 and 15 – 29 mL/minute/1. There was no statistically significant improvement in HDL-C or TG at any LIVALO dose. Samantha Karr, PharmD, FCCP, BCPS, BCACP, BC-ADM. Allonen J, Nieminen MS, Lokki M, et al. , Clinical Pharmacology, Facts & Comparisons eAnswers, Lexicomp Online, Micromedex Solutions, UpToDate), and. Vytorin dosing is 10/10 mg/day to 10/40 mg/day orally once daily. LIVALO livalo package insert is contraindicated in patients with active liver disease including unexplained persistent elevations of hepatic transaminase levels [see Contraindications , Warnings and Precautions ]. Montgomery, AL: Kowa Pharmaceuticals America, Inc; 2013. LIVALO (pitavastatin) is an inhibitor of HMG-CoA reductase. 2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of LIVALO. Supplements and Featured Publications, PCSK9 Inhibitors: A Guide for Managed Care.